SACUBITRIL; VALSARTAN | A213764 | ALKEM LABORATORIES LTD
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Novartis Pharmaceuticals Corporation v. Alkem Laboratories Ltd. 1 patentANDA 213764sacubitril/valsartan | D. Del. | 2022-01-07 | Terminated 2022-11-21 | — |
Novartis Pharmaceuticals Corporation v. Torrent Pharma Inc., et al. 4 patentsANDA 213764, 213631, 213680, 213605, 213676, 213808, 213809, 213671, 213577, 213604sacubitril/valsartan | D. Del. | 2019-10-17 | Terminated 2024-09-06 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$0.5859
per ea
Lowest NADAC/Unit
$0.5306
per ea
Brand NDCs
0
Generic NDCs
11
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00904758104SACUBITRIL-VALSARTAN 97-103 MG | $0.5859 | EA | Generic | — | 2026-06-17 |
| 67877070960SACUBITRIL-VALSARTAN 97-103 MG | $0.5859 | EA | Generic | — | 2026-06-17 |
| 67877095051SACUBITRIL-VALSARTAN 97-103 MG | $0.5859 | EA | Generic | — | 2026-06-17 |
| 67877095060SACUBITRIL-VALSARTAN 97-103 MG | $0.5859 | EA | Generic | — | 2026-06-17 |
| 00904758204SACUBITRIL-VALSARTAN 49-51 MG | $0.5485 | EA | Generic | — | 2026-06-17 |
| 67877070860SACUBITRIL-VALSARTAN 49-51 MG | $0.5485 | EA | Generic | — | 2026-06-17 |
Showing 6 of 11 NDCs.
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.